Rohm and Haas's Ion Exchange Resin Division is offering an oral drug formulation service based on its advanced released technologies, supported by its Flo Vitro dissolution test methodology.
The service will offer a cost-effective way for customers to reduce their development time and facilitate their formulation needs.
Rohm and Haas will provide services ranging from simple, initial screening studies, to the development of resinates (drug-resin complexes), supported by Flo Vitro dissolution test methodology.
Rohm and Haas's advanced release technologies solve a range of formulation issues such as stability, poor solubility, low melting point, deliquescence/hygroscopicity, polymorphism, taste-masking or controlled release for numerous commercial drugs.
Its Amberlite and Duolite ion exchange resins are supplied in powder form and manufactured according to cGMP standards.
Rohm and Haas's buccal dissolution test methodology has been demonstrated to correlate with human taste perception to evaluate taste-masking in liquid and dissolve-in-the-mouth dosage forms.
Flo Vitro technology is an in-vitro dissolution test method that handles ion exchange resins and is compatible with all common oral dosage forms.
This method will be used to demonstrate the dissolution profile of the formulations as they are developed.
Flo Vitro technology has the ability to generate dissolution curves that match plasma profiles directly without the need for mathematical modelling.
The Flo Vitro technology is available from Rohm and Haas either as an analytical service or for use under license.
Rohm and Haas will be exhibiting the service at AAPS Annual Meeting and Expo.
On 20 November 20 a poster entitled 'Exploring Suitability and Feasibility of a Novel In Vitro Dissolution System' featuring Rohm and Haas's Flo Vitro technology will be presented by the Food and Drug Administration.
